GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (LTS:0QCO) » Definitions » Total Long-Term Liabilities

Pharming Group (LTS:0QCO) Total Long-Term Liabilities : €102.1 Mil (As of Mar. 2025)


View and export this data going back to 2007. Start your Free Trial

What is Pharming Group Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Pharming Group's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was €102.1 Mil.

Pharming Group Total Long-Term Liabilities Historical Data

The historical data trend for Pharming Group's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Total Long-Term Liabilities Chart

Pharming Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 130.02 139.50 152.42 152.32 100.39

Pharming Group Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.16 106.89 108.02 100.39 102.08

Pharming Group Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Pharming Group Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Pharming Group's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (LTS:0QCO) » Definitions » Total Long-Term Liabilities
Comparable Companies
XAMS:VVY XAMS:GLPG VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX SMMT RPRX OCSE:GMAB XKRX:196170 INCY HKSE:02269 INSM HKSE:01801
Traded in Other Exchanges
PHAR:USA PHGUF:USA PHARM:Netherlands PHARMa:UK PHGN:Germany
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Website
https://www.pharming.com
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group Headlines

No Headlines